BRPI0510340A - derivados de 3-heterociclil-4-feniltriazol como inibidores do receptor via da vasopressina - Google Patents

derivados de 3-heterociclil-4-feniltriazol como inibidores do receptor via da vasopressina

Info

Publication number
BRPI0510340A
BRPI0510340A BRPI0510340-1A BRPI0510340A BRPI0510340A BR PI0510340 A BRPI0510340 A BR PI0510340A BR PI0510340 A BRPI0510340 A BR PI0510340A BR PI0510340 A BRPI0510340 A BR PI0510340A
Authority
BR
Brazil
Prior art keywords
het
alkyl
alkyloxy
disease
heterocyclyl
Prior art date
Application number
BRPI0510340-1A
Other languages
English (en)
Inventor
Justin Stephen Bryans
Patrick Stephen Johnson
Thomas Rickmans
Alan Stobie
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0409502A external-priority patent/GB0409502D0/en
Priority claimed from GB0415888A external-priority patent/GB0415888D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of BRPI0510340A publication Critical patent/BRPI0510340A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

DERIVADOS DE 3-HETEROCICLIL-4-FENILTRIAZOL COMO INIBIDORES DO RECEPTOR VIA DA VASOPRESSINA Compostos de fórmula (I): ou um derivado farmacêuticamente aceitável seu, em que R representa alquil C~ 1-6~ (opcionalmente substituído por alquilóxi C~ 1-6~ ou Het), ou alquilóxi C~ 1-6~); R¬ 1¬ e R¬ 2¬, independentemente, representam hidrogênio, halogênio ou alquil C~ 1-6~; o anel A representa Het¬ 1¬; X representa O ou NR¬ 3¬; R¬ 3¬ representa hidrogênio ou alquil C~1-6~; o anel B representa um grupo fenil ou Het¬ 2¬, qualquer um dos quais pode ser opcionalmente substituído com um ou mais grupos selecionados de halogênio, CN, alquilóxi C~ 1-6~, CF~ 3~, alquil C~ 1-6~, NH~ 2~ e NO~ 2~; Het e Het¬ 1¬, independentemente, representam um grupo heterocíclico saturado, parcialmente insaturado ou aromático de 5 ou 6 membros, compreendendo ou (a) de1 a 4 átomos de nitrogênio, (b) um oxigênio ou um átomo de enxofre ou (c) 1 átomo de oxigénio ou 1 átomo de enxofre e 1 ou 2 átomos de nitrogênio são úteis para o tratamento da ansiedade, doença cardiovascular (incluindo angina, aterosclerose, hipertensão, falência cardíaca, edema, hipernatremia), dismenorréia (primária e secundária), endometriose, emese (incluindo doença de deslocamento), retardo de crescimento intrauterino, inflamação (incluindo artrite reumatóide), dor intermenstrual, preclâmpsia; ejaculação prematura, trabalho prematuro (nascimento prematuro) ou doença de Raynaud.
BRPI0510340-1A 2004-04-28 2005-04-18 derivados de 3-heterociclil-4-feniltriazol como inibidores do receptor via da vasopressina BRPI0510340A (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0409502A GB0409502D0 (en) 2004-04-28 2004-04-28 Triazole derivatives
US57625204P 2004-06-02 2004-06-02
GB0415888A GB0415888D0 (en) 2004-07-15 2004-07-15 Triazole derivatives
US60108204P 2004-08-12 2004-08-12
PCT/IB2005/001062 WO2005105779A1 (en) 2004-04-28 2005-04-18 3-heterocyclyl-4-phenyl-triazole derivatives as inhibitors of the vasopressin v1a receptor

Publications (1)

Publication Number Publication Date
BRPI0510340A true BRPI0510340A (pt) 2007-10-30

Family

ID=46045409

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0510340-1A BRPI0510340A (pt) 2004-04-28 2005-04-18 derivados de 3-heterociclil-4-feniltriazol como inibidores do receptor via da vasopressina

Country Status (7)

Country Link
US (1) US20070225333A1 (pt)
EP (1) EP1742932A1 (pt)
JP (1) JP2007534740A (pt)
BR (1) BRPI0510340A (pt)
CA (1) CA2563963A1 (pt)
MX (1) MXPA06012510A (pt)
WO (1) WO2005105779A1 (pt)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723362B2 (en) * 2004-01-08 2010-05-25 Syngenta Crop Protection, Inc. Pesticidal heterocyclic dihaloallyl compounds
AP2007004047A0 (en) 2005-01-20 2007-06-30 Pfizer Ltd Substituted triazole derivatives as oxtocin antagonists
WO2006130986A1 (en) * 2005-06-09 2006-12-14 Merck Frosst Canada Ltd. Azacyclohexane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
JO2769B1 (en) 2005-10-26 2014-03-15 جانسين فارماسوتيكا ان. في Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor
DE102006024024A1 (de) 2006-05-23 2007-11-29 Bayer Healthcare Aktiengesellschaft Substituierte Arylimidazolone und -triazolone sowie ihre Verwendung
AU2007260527A1 (en) * 2006-06-12 2007-12-21 Merck Frosst Canada Ltd. Azetidine derivatives as inhibitors of stearoyl-coenzyme A delta-9 desaturase
JO2642B1 (en) 2006-12-08 2012-06-17 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
JO2849B1 (en) 2007-02-13 2015-03-15 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
CN101663292A (zh) 2007-04-23 2010-03-03 詹森药业有限公司 作为快速解离的多巴胺2受体拮抗剂的4-烷氧基哒嗪衍生物
MX2009011414A (es) * 2007-04-23 2009-11-05 Janssen Pharmaceutica Nv Derivados de piridina como antagonistas del receptor de dopamina 2 de disociacion rapida.
AU2008240729B2 (en) 2007-04-23 2012-08-23 Janssen Pharmaceutica N.V. Thia(dia)zoles as fast dissociating dopamine 2 receptor antagonists
CA2729313C (en) 2008-07-03 2016-08-30 Janssen Pharmaceutica Nv Substituted 6-(1-piperazinyl)-pyridazines as 5-ht6 receptor antagonists
KR101609218B1 (ko) 2008-07-31 2016-04-05 얀센 파마슈티카 엔.브이. 속해리성 도파민 2 수용체 길항제로서의 피페라진-1-일-트리플루오로메틸-치환된-피리딘
DE102008060967A1 (de) 2008-12-06 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Substituierte Phenylsulfonyltriazolone und ihre Verwendung
DE102010001064A1 (de) 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
AU2010232923A1 (en) * 2009-04-03 2011-11-03 Medisyn Technologies, Inc. Compositions for treatment of Alzheimer's disease
DE102009028929A1 (de) * 2009-08-27 2011-07-07 Bayer Schering Pharma Aktiengesellschaft, 13353 Heterocyclisch-substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
MY169980A (en) 2010-02-27 2019-06-19 Bayer Ip Gmbh Bisaryl-linked aryltriazolones and their use
DE102010040187A1 (de) 2010-09-02 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Substituierte N-Phenethyl-triazolonacetamide und ihre Verwendung
DE102010040924A1 (de) 2010-09-16 2012-03-22 Bayer Schering Pharma Aktiengesellschaft Substituierte Phenylacet- und Phenylpropanamide und ihre Verwendung
CA2811192C (en) 2010-10-01 2018-02-27 Taisho Pharmaceutical Co., Ltd. 1,2,4-triazolone derivative
WO2014124392A1 (en) * 2013-02-08 2014-08-14 University Of Iowa Research Foundation Diagnostic tools to predict onset of preeclampsia
TWI679205B (zh) 2014-09-02 2019-12-11 日商日本新藥股份有限公司 吡唑并噻唑化合物及醫藥
US10138236B2 (en) 2014-09-24 2018-11-27 Bayer Pharma Aktiengesellschaft Factor xia-inhibiting pyridobenzazepine and pyridobenzazocine derivatives
SG11201703199UA (en) 2014-11-03 2017-05-30 Bayer Pharma AG Hydroxyalkyl-substituted phenyltriazole derivatives and uses thereof
CN109071464A (zh) 2016-05-03 2018-12-21 拜耳制药股份公司 氧代烷基取代的苯基***衍生物及其用途
EP3452472A1 (en) 2016-05-03 2019-03-13 Bayer Aktiengesellschaft Hydroxyalkyl-substituted heteroaryltriazole derivatives and uses thereof
AR108263A1 (es) 2016-05-03 2018-08-01 Bayer Pharma AG Procedimiento para la preparación de derivados de 1-fenilo-1,2,4-triazol sustituidos por 5-hidroxialquilo
EP3452469A1 (en) 2016-05-03 2019-03-13 Bayer Pharma Aktiengesellschaft Fluoroalkyl-substituted aryltriazole derivatives and uses thereof
WO2017191105A1 (en) 2016-05-03 2017-11-09 Bayer Pharma Aktiengesellschaft Amide-substituted aryltriazole derivatives and uses thereof
US9988367B2 (en) 2016-05-03 2018-06-05 Bayer Pharma Aktiengesellschaft Amide-substituted pyridinyltriazole derivatives and uses thereof
JOP20190072A1 (ar) * 2016-10-13 2019-04-07 Glaxosmithkline Ip Dev Ltd مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم
US10927098B2 (en) 2016-10-20 2021-02-23 Bayer Pharma Aktiengesellschaft Hydroxyalkyl-substituted triazole derivatives and uses thereof
CA3079770A1 (en) 2017-10-24 2019-05-02 Bayer Pharma Aktiengesellschaft Amine substituted triazole derivatives and uses thereof
WO2019081291A1 (en) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft PRODRUGS OF SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF
WO2019081307A1 (en) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF
SI3700913T1 (sl) 2017-10-24 2022-02-28 Bayer Aktiengesellschaft Predzdravila derivatov substituiranega triazola in njihove uporabe
US11230540B2 (en) 2017-10-24 2022-01-25 Bayer Pharma Aktiengesellschaft Substituted triazole derivatives and uses thereof
WO2019081303A1 (en) 2017-10-24 2019-05-02 Bayer Pharma Aktiengesellschaft SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF
WO2019081302A1 (en) 2017-10-24 2019-05-02 Bayer Pharma Aktiengesellschaft SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF
CN111440147B (zh) * 2020-05-19 2023-03-07 苏州卫生职业技术学院 N-(2-甲基-5-氨基苯基)-4-(3-吡啶基)-2-嘧啶胺的合成方法
CN116194441A (zh) * 2020-07-23 2023-05-30 豪夫迈·罗氏有限公司 作为加压素受体v1 a拮抗剂的环己基取代的***
CN116234801A (zh) * 2020-07-23 2023-06-06 豪夫迈·罗氏有限公司 作为加压素受体v1 a拮抗剂的杂芳基-甲基取代的***

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3840597A (en) * 1971-02-24 1974-10-08 Riker Laboratories Inc Substituted 2-phenoxy alkane-sulfonanilides
DE2756113A1 (de) * 1977-12-16 1979-06-21 Thomae Gmbh Dr K Neue 4-hydroxy-2h-1,2-benzothiazin- 3-carboxamid-1,1-dioxide, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
CA2113787A1 (en) * 1993-01-29 1994-07-30 Nobuyuki Hamanaka Carbocyclic sulfonamides
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
JP3778581B2 (ja) * 1993-07-05 2006-05-24 三菱電機株式会社 半導体装置およびその製造方法
US5344991A (en) * 1993-10-29 1994-09-06 G.D. Searle & Co. 1,2 diarylcyclopentenyl compounds for the treatment of inflammation
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
US5521213A (en) * 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
JP3181190B2 (ja) * 1994-12-20 2001-07-03 日本たばこ産業株式会社 オキサゾール誘導体
JP2636819B2 (ja) * 1994-12-20 1997-07-30 日本たばこ産業株式会社 オキサゾール系複素環式芳香族化合物
US6143747A (en) * 1995-01-20 2000-11-07 G. D. Searle & Co. Bis-sulfonamide hydroxyethylamino retroviral protease inhibitors
US5633272A (en) * 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
WO1996026940A1 (fr) * 1995-03-01 1996-09-06 Kyowa Hakko Kogyo Co., Ltd. Derives d'imidazoquinazoline
US5968974A (en) * 1995-07-19 1999-10-19 Merck & Co., Inc. Method of treating colonic adenomas
EP0840608B1 (en) * 1995-07-21 2004-10-06 Savvipharm Inc. Orotate salts of 5-amino or substituted amino 1,2,3-triazoles for treatment of neoplasms
ATE196629T1 (de) * 1995-07-21 2000-10-15 Nycomed Austria Gmbh Derivate von benzosulfonamiden als hemmer des enzym cyclooxygenase ii
US5981576A (en) * 1995-10-13 1999-11-09 Merck Frosst Canada, Inc. (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors
US6020343A (en) * 1995-10-13 2000-02-01 Merck Frosst Canada, Inc. (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors
US6057319A (en) * 1995-10-30 2000-05-02 Merck Frosst Canada & Co. 3,4-Diaryl-2-hydroxy-2,5-dihydrofurans as prodrugs to cox-2 inhibitors
US6180651B1 (en) * 1996-04-04 2001-01-30 Bristol-Myers Squibb Diarylmethylidenefuran derivatives, processes for their preparation and their uses in therapeutics
EE03685B1 (et) * 1996-04-12 2002-04-15 G.D. Searle & Co. Asendatud benseensulfoonamiidi derivaadid kui COX-2 inhibiitorite eelravimid
US5883267A (en) * 1996-05-31 1999-03-16 Merck & Co., Inc. Process for making phenyl heterocycles useful as cox-2 inhibitors
US5861419A (en) * 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
ATA16597A (de) * 1997-02-03 1998-04-15 Nycomed Austria Gmbh Neue substituierte p-sulfonylaminobenzol- sulfonsäureamide
EP1006114B1 (en) * 1997-04-11 2003-01-22 Grelan Pharmaceutical Co., Ltd. Pyrazole derivatives and cox inhibitors containing them
US6127545A (en) * 1997-04-18 2000-10-03 Merck & Co., Inc. Process for making 2-aryl-3-aryl-5-halo pyridines useful as COX-2 inhibitors
US6130334A (en) * 1998-04-15 2000-10-10 Merck & Co., Inc. Process for making 2-aryl-3-aryl-5-halo pyridines useful as COX-2 inhibitors
US6077850A (en) * 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation
US6034256A (en) * 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
US6043252A (en) * 1997-05-05 2000-03-28 Icos Corporation Carboline derivatives
KR20010014288A (ko) * 1997-06-30 2001-02-26 오르토-맥네일 파마슈티칼, 인코퍼레이티드 염증성 질환의 치료에 유용한 2-치환된 이미다졸
AP9801302A0 (en) * 1997-07-23 2000-01-23 Pfizer Indole compounds as anti-inflammatory/analgesic agents..
US6307047B1 (en) * 1997-08-22 2001-10-23 Abbott Laboratories Prostaglandin endoperoxide H synthase biosynthesis inhibitors
US5925769A (en) * 1997-09-09 1999-07-20 Ortho Pharmaceutical, Corp. Acetylenic 1,5-diarylpyrazoles as antiinflammatory agents
US6046217A (en) * 1997-09-12 2000-04-04 Merck Frosst Canada & Co. 2,3,5-trisubstituted pyridines as inhibitors of cyclooxygenase-2
US6140515A (en) * 1997-09-24 2000-10-31 Merck & Co., Inc. Process of making 3-aryloxy, 4-aryl furan-2-ones useful as inhibitors of COX-2
US6040450A (en) * 1997-09-25 2000-03-21 Merck & Co., Inc. Process for making diaryl pyridines useful as cox-2-inhibitors
US6080876A (en) * 1997-10-29 2000-06-27 Merck & Co., Inc. Process for making phenyl heterocycles useful as COX-2 inhibitors
US6133292A (en) * 1997-10-30 2000-10-17 Merck Frosst Canada & Co. Diaryl-5-alkyl-5-methyl-2-(5H)-furanones as selective cyclooxygenase-2-inhibitors
JP3256513B2 (ja) * 1998-02-11 2002-02-12 ファイザー製薬株式会社 ベンゾイミダゾールシクロオキシゲナーゼ−２阻害剤
US5994379A (en) * 1998-02-13 1999-11-30 Merck Frosst Canada, Inc. Bisaryl COX-2 inhibiting compounds, compositions and methods of use
EP1085845A2 (en) * 1998-06-08 2001-03-28 Advanced Medicine, Inc. Multibinding inhibitors of cyclooxygenase-2
JP2000063363A (ja) * 1998-08-12 2000-02-29 Yamanouchi Pharmaceut Co Ltd 新規なトリアゾール誘導体
KR100295206B1 (ko) * 1998-08-22 2001-07-12 서경배 디아릴벤조피란유도체및이를함유하는시클로옥시게네이즈-2저해제조성물
US6077869A (en) * 1998-10-29 2000-06-20 Ortho-Mcneil Pharmaceutical, Inc. Aryl phenylhydrazides as selective COX-2 inhibitors for treatment of inflammation
US6376519B1 (en) * 1999-06-16 2002-04-23 Temple University-Of The Commonwealth Of Higher Education 1-(4-sulfamylaryl)-3-substituted-5-aryl-2-pyrazolines and inhibitors of cyclooxygenase-2
MXPA00006605A (es) * 1999-07-02 2004-12-09 Pfizer Compuestos de carbonil-indol biciclicos como agentes antiinflamatorios/analgesicos.
US6077868A (en) * 1999-07-20 2000-06-20 Wisconsin Alumni Research Foundation Selective inhibition of cyclooxygenase-2
US6306890B1 (en) * 1999-08-30 2001-10-23 Vanderbilt University Esters derived from indolealkanols and novel amides derived from indolealkylamides that are selective COX-2 inhibitors
US6083969A (en) * 1999-10-20 2000-07-04 Ortho-Mcneil Pharaceutical, Inc. 1,3- and 2,3-diarylcycloalkano and cycloalkeno pyrazoles as selective inhibitors of cyclooxygenase-2 and antiinflammatory agents
AU2000223275A1 (en) * 2000-02-08 2001-08-20 Yamanouchi Pharmaceutical Co..Ltd. Novel triazole derivatives
US6359182B1 (en) * 2000-10-26 2002-03-19 Duke University C-nitroso compounds and use thereof
US7084145B2 (en) * 2002-10-25 2006-08-01 Pfizer Inc. Triazole compounds useful in therapy

Also Published As

Publication number Publication date
JP2007534740A (ja) 2007-11-29
CA2563963A1 (en) 2005-11-10
US20070225333A1 (en) 2007-09-27
EP1742932A1 (en) 2007-01-17
MXPA06012510A (es) 2006-12-15
WO2005105779A1 (en) 2005-11-10

Similar Documents

Publication Publication Date Title
BRPI0510340A (pt) derivados de 3-heterociclil-4-feniltriazol como inibidores do receptor via da vasopressina
ATE425142T1 (de) Inhibitoren von c-jun n-terminal kinasen (jnk)
PE20220905A1 (es) Pirroles triciclicos condensados como moduladores de alfa-1 antitripsina
NO341631B1 (no) Hydroksybenzamidderivater og deres anvendelse, fremgangsmåte for fremstilling og farmasøytiske sammensetninger
AR057989A1 (es) Derivados de indol-2-il-amida 1,5-sustituida. procesos de obtencion y composiciones farmaceuticas
BRPI0515133A (pt) derivados de uréia como bloqueadores do canal de cálcio
BRPI0514458A (pt) triazolbenzodiazepinas e seu uso como antagonistas de vasopressina
BRPI0708016A2 (pt) composto ou um sal, solvato ou n-óxido do mesmo, composição farmacêutica, uso de um composto ou um sal, solvato ou n-óxido do mesmo, e, método para o tratamento e/ou prevenção de distúrbios
NO20064089L (no) Kondensert ring 4-oksopyrimidinderivat
CY1105899T1 (el) Πυριδινοϋλοπιπepιδινες ως 5-ht1f αγωνιστες
CO5640104A2 (es) Derivados de aminoisoxazol activos como inhibidores de quinasa
BRPI0506848A (pt) composto,uso do mesmo, formulação farmacêutica e produto farmacêutico
HRP20090151T3 (en) Indozolone derivatives as 11b-hsd1 inhibitors
EA201101566A1 (ru) Производные имидазола и их применение в качестве модуляторов циклинзависимых киназ
EA201070890A1 (ru) Замещенные ариламидные производные оксазепинопиримидона
EA200971062A1 (ru) Производные ариламидпиримидона
PE20091524A1 (es) Derivados de 2-aminopirimidina
EA200971063A1 (ru) Ариламидпиримидоновые соединения
EA200500717A1 (ru) Новые соединения имидазопиридина, способ их получения и фармацевтические композиции, которые их содержат
NO20074883L (no) Biologisk nedbrytbare gasshydratinhibitorer
BRPI0408248A (pt) derivados azabicìclicos de piridiloximetila e de benzisoxazol
JP2017509611A (ja) 置換ピリドン及びピラジノン、並びに好中球エラスターゼ活性の阻害剤としてのその使用
TW200616997A (en) The preparation method for 6-substituted-1-methyl-1h-benzoimidazol derivatives and their preparation imtermediates
BR0009582A (pt) Composto, composição farmacêutica, e, processopara o tratamento de uma condição de doençaselecionada de artrite reumatóide, doença dealzheimer, câncer, esquizofrenia, edema, rinitealérgica, inflamação, dor, hipermobilidadegastrointestinal , asma gástrica, refluxogastroesfageal, ansiedade, emese, doença dehuntington, psicoses incluindo depressão,hipertensão, enxaqueca e urticária
PE20040905A1 (es) Derivados biciclicos como inhibidores de tirosina quinasa

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A, 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.